DYAI Share Price Performance
US$0.72
-0.34 (-31.89%)
92.0% undervalued intrinsic discount
US$9.00
Fair Value
Price US$0.72
AnalystHighTarget US$9.00
AnalystConsensusTarget US$5.67
AnalystLowTarget US$5.00
Fair ValueUS$9.00
Share Pricen/a
Dyadic International, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 5 Fair Values set on narratives written by author
DYAI Community Narratives
AN
Fair Value
·Fair Value US$9 92.0% undervalued intrinsic discount
Animal Free Protein Platforms And Partnerships Will Transform Long Term Earnings Quality
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value US$5.67 87.3% undervalued intrinsic discount
Analysts Weigh New Risks and Opportunities as Dyadic International Faces Lower Growth Projections
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value US$5 85.6% undervalued intrinsic discount
Animal Free Enzymes And Proteins Will Face Delays Yet Ultimately Unlock Long-Term Potential
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Animal Free Protein Platforms And Partnerships Will Transform Long Term Earnings Quality
Catalysts About Dyadic International Dyadic International develops and licenses fungal based protein production platforms used to manufacture animal free proteins, enzymes and biologics for life sciences, food and industrial applications. What are the underlying business or industry changes driving this perspective?Read more
AN
US$9
92.0% undervalued intrinsic discount
Fair Value
Profit Margin
16.24%
Future PE
67.76x
Price in 2029
US$11.12
Animal Free Enzymes And Proteins Will Face Delays Yet Ultimately Unlock Long-Term Potential
Catalysts About Dyadic International Dyadic International develops and commercializes fungal based protein production platforms to supply animal free enzymes and proteins for life sciences, food and nutrition, and bioindustrial markets. What are the underlying business or industry changes driving this perspective?Read more
AN
US$5
85.6% undervalued intrinsic discount
Fair Value
Profit Margin
16.03%
Future PE
163.97x
Price in 2028
US$6.18
Analysts Weigh New Risks and Opportunities as Dyadic International Faces Lower Growth Projections
Key Takeaways Transitioning to commercial sales and broad product launches positions the company to improve operating margins and gain more predictable, recurring revenue streams. Strategic partnerships, scalable technology, and sustainability focus give competitive advantages and support accelerating market adoption and long-term profit growth.Read more
AN
US$5.67
87.3% undervalued intrinsic discount
Fair Value
Profit Margin
22.24%
Future PE
61.61x
Price in 2028
US$6.93
Trending Discussion
Recently Updated Narratives
AN
Animal Free Protein Platforms And Partnerships Will Transform Long Term Earnings Quality
Fair Value: US$9 92.0% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Animal Free Enzymes And Proteins Will Face Delays Yet Ultimately Unlock Long-Term Potential
Fair Value: US$5 85.6% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
DYAI: Near-Term Commercial Portfolio Catalysts Will Drive Upside Potential
Fair Value: US$5.67 87.3% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Dyadic International, Inc. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
- -0.20
- 26.10%
- -191.50%
- -1,234.5%
About DYAI
- Founded
- 1979
- Employees
- 5
- CEO
- WebsiteView website
Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd; license agreement with Rubic One Health to develop various livestock vaccines; and sub-license agreement with Phibro Animal Health/Abic Biological Laboratories to develop vaccines and treatments for livestock diseases. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
